News | January 04, 2022
Domestic and emerging markets will drive pharma growth: ICRA
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
The product is expected to be available in a week’s time
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Flattish volume growth and subdued new launches were key factors for last month
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
The hospital has recently launched Radionuclide therapy
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
Subscribe To Our Newsletter & Stay Updated
